Effect of GA/18β treatments
infection
INFECTION, DISEASE PROGRESSION
Our findings highlight the immunomodulatory effects of the GA/18β drug, as evidenced through the assessment of interleukins and SARS-CoV-2 specific antibodies. In general, it has been reported that interleukins are molecules with high variation in basal levels due to various subject-specific conditions, such as sex, comorbidities, initial symptoms that could differ concerning the onset of the infection, sample collection time, and other factors. These variables can consequently increase the standard error of the data (Modulation of serum levels of IL-17A, TNF-α, IL-6, IL-8, and IL-1βfor each group. Mean ± standard error values are reported. Statistically significant differences compared to control are indicated by *(group A) or + (group B) when p ≤ 0.05. The concentration data, the lower and upper values, and limits of detection for these interleukins are shown in Relative serum levels of IL-2 and IFN-γ over disease progression. Mean ± standard error values are reported. Statistically significant differences compared to control are indicated by * (group A) or + (group B) when p ≤ 0.05. The concentration data, the lower and upper values, and limits of detection for these interleukins are shown in Furthermore, it was observed that the administration of GA/18β doses led to a reduction in the intake of concomitant medications. This suggests that the GA/18β drug mitigates symptoms in patients during the 15-day treatment period. Notably, within the initial 7 days, when COVID-19 symptoms are most pronounced, nebulized treatment contributed to a decrease in the number of patients requiring concomitant medications. During the first nebulization week, discontinuation of concomitant medication use was observed in 100%, 94%, and 77% of subjects receiving treatments doses A, B, and control group, respectively (Use and discontinuation of concomitant medications during the trial by treatment group.Discontinuation percentages were calculated based on the total number of subjects using concomitant medicines. Values are shown as percentages.